Improvement in 5-Fluorouracil (5-FU) and 5-Fluoro-2'- Deoxyuridine (FdUrd) Concentration by 5-Fluorouracil- Polyethylene-Glycol-Liposomes in Abdominal Stop-Flow: Treatment of VX2 Liver-Tumor-Bearing Rabbits

References

• FahIke J, Ridwelski K, Lippert H. High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorec-tal carcinoma. Int J Colorectal Dis 1999; 14: 128–30.
   PubMed Web of Science ®Google Scholar
• Gieseler F.The dilemma of gastroenterological oncology: we know a lot but we still achieve too little. Int J Colorectal Dis 2000; 15: 112–3.
   PubMed Web of Science ®Google Scholar
• Pahlman L. Neoadjuvant and adjuvant radio- and radio-chemotherapy of rectal carcinomas. Int J Colorectal Dis 2000; 15: 1–8.
   PubMed Web of Science ®Google Scholar
• Päuser S, Reszka R, Pohlen U, Buhr HJ, Berger G. Evaluation of efficient chemoembolization mixtures by magnet-ic resonance imaging therapy monitoring: an experimental study on the VX2 tumor in rabbit liver. Cancer Res 1996; 56 (8): 1863–7.
   PubMed Web of Science ®Google Scholar
• Link K H, Kornmann M, Leder GH, et al. Regional chemotherapy directed by individual chemosensitivity testing in vitro: a prospective decision-aiding trial. Clin Cancer Res 1996; 2: 1469–74.
   PubMed Web of Science ®Google Scholar
• Ensminger W, Gyves J. Clinical pharmacology of hepat-ic artery chemotherapy. Sem Oncol 1983; 10: 176–82.
   PubMed Web of Science ®Google Scholar
• Averbach AM, Stuart OA, Sugarbaker TA, et al. Pharmacokinetic studies of intra-aortic stop-flow infusion with 14C-labeled mitomycin C. J Surg Res 1995; 59: 415–9.
   PubMed Web of Science ®Google Scholar
• Müller H, Aigner KR. Palliation of recurrent rectal can-cer with intra-arterial mitomycin c/5-FU via Jet Port aortic bifurcation catheter. Reg Cancer Treat 1990; 3: 147–51.
   Google Scholar
• Eibel-Eibesfeld B, Störz V, Kummermehr J, Schalhorn A. Basic investigations on interaction of 5-fluorouracil and tumor ischemia in the Treatment of liver malignances. In: Schlag P, Hohenberg P, Metzger U (ed): Combined Modality of Gastrointestinal Tract Cancer. Recent Results in Cancer Research 110, Springer Verlag Berlin, 1988: 187-195.
   Google Scholar
• Tannock IF. Toxicity of 5-FU for aerobic and hypoxic cells in two murine tumors. Cancer Chemother Pharmacol 1987; 19: 53–6.
   PubMed Web of Science ®Google Scholar
• Bally MB, Masin D, Nayar R, Cullis PR, Mayer D. Transfer of liposomal drug carriers from blood to the peri-toneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol 1994; 34: 137–46.
   PubMed Web of Science ®Google Scholar
• Treat J, Greenspan A. Forst D, et al. Antitumor activi-ty of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst 1990; 82 (21): 1706–10.
   Google Scholar
• Rougier P, Laplanche A, Hay JM. Hepatic arterial infu-sion of floxuridine in Patients with liver metastases from col-orectal carcinoma. Long-term results of a prospective random-ized trail. J Clin Oncol 1992; 10: 112–8.
   Google Scholar
• Yatvin MB, Lelkes PI. Clinical prospects for liposomes. Med Phys 1982; 9 (2): 149–75.
   PubMed Web of Science ®Google Scholar
• Ryman BE, Tyrrell DA. Liposome - bags of potential. In Cambell PN and Marshal RD (ed): Essays Biochemistry, New York, Academic Press, 1980, vol 16: 49–98.
   Google Scholar
• Gabizon A, Catane R, Uziely B, Kaufman B, Safra T. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyl-ene-glycol coated liposomes (DOXIL). Cancer Res 1994; 54: 987–92.
   PubMed Web of Science ®Google Scholar
• Mayer LD, Tai LC, Bally MB, Mitilenes GN, Ginsberg RS, Cullis PR. Characterization of liposomal systems contain-ing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1990; 1025: 143–51.
   PubMed Web of Science ®Google Scholar
• Pauser S, Reszka R, Wagner S, Wolf KJ, Buhr HJ, Berger G. Liposome encapsulates superparamagnetic iron oxide particles as markers in an MRT-guides search for tumor-specific drug carriers. Anticancer Drug Des 1997; 12: 125–35.
   PubMedGoogle Scholar
• Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacoki-netics and antitumor therapeutic efficiency. Proc Natl Acad Sci USA 1991; 88: 11460–4.
   PubMed Web of Science ®Google Scholar
• Jung m., Berger G, Pohlen U, Pauser S, Reszka R, Buhr HJ. Simultaneous determination of 5-fluorooucil and is active metabolites in serum and tissue by high-performance liquid chromatography. J Chromatogr B Biomed Sci App 1997; 702: 193–202.
   PubMed Web of Science ®Google Scholar
• Heinemann V. Present and future treatment of pancre-atic cancer. Semin Oncol 2002; 29 (3 Suppl 9): 23-31.
   Google Scholar
• Sagar PM, Pemberton JH. Surgical management of locally recurrent rectal cancer. Br J Surg 1996; 83 (3): 293–304.
   PubMed Web of Science ®Google Scholar
• Gunderson LL, Martin JK, O'Connell MJ, Beart RW, Kvols LK, Nagorney DM. Local control and survival in locally advanced gastrointestinal cancer. Int J Radiat Oncol Biol Phys 1986; 12 (4): 661–5.
   PubMed Web of Science ®Google Scholar
• Kerr DJ, Los G. Pharmacokinetic principles of locore-gional chemotherapy. Cancer Surv 1993; 17: 105–22.
   PubMedGoogle Scholar
• Lienard D, Eggermont AM, Koops HS, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melpha-lan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9 (5): 491–502.
   PubMed Web of Science ®Google Scholar
• Rossi CR, Foletto M, Di Filippo F, et al. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblas-tic perfusion. Cancer 1999; 86 (9): 1742–9.
   PubMed Web of Science ®Google Scholar
• The meta-analysis group in cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88: 252–8.
   Google Scholar
• Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcino-ma metastatic to the liver: Is there a survival difference? Meta-analysis of the published literature. Cancer 1996; 78: 1639–45.
   PubMed Web of Science ®Google Scholar
• Aigner K. Aortic stop-flow infusion (ASI) and hypoxic abdominal perfusion (HAP) for disseminated bulk peritoneal carcinomatosis: rational and technique. Reg Cancer Treat 1993; 6: 3.
   Google Scholar
• Klein ES, Ben-An i GY, Papa MZ, Adar R, Bass A. Vascular complications of total abdominal perfusion and aortic stop-flow infusion. J Surg Oncol 1996; 61 (1): 17–9.
   Google Scholar
• Wanebo HJ, Chung MA, Levy Al, Turk PS, Vezeridis MP, Belliveau JF. Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon-occlu-sion technique. Ann Surg Oncol 1996; 3 (3): 295–303.
   PubMed Web of Science ®Google Scholar
• Pruijn FB, van Daalen M, Holford NH, Wilson WR. Mechanisms of enhancement of the antitumour activity of mel-phalan by the tumour-blood-flow inhibitor 5,6-dimethylxan-thenone-4-acetic acid. Cancer Chemother Pharmacol 1997; 39 (6): 541–6.
   PubMed Web of Science ®Google Scholar
• Ehrnrooth E, von der Maase H, Sorensen BS, Poulsen JH, Horsman MR. The ability of hypoxia to modify the gene expression of thymidylate synthase in tumour cells in vivo. Int J Radiat Biol 1999; 75 (7): 885–91.
   PubMed Web of Science ®Google Scholar
• Achison M, Hupp TR. Hypoxia attenuates the p53 response to cellular damage. Oncogene 2003; 22 (22): 3431–40.
   PubMed Web of Science ®Google Scholar
• Heidelberger C, Chaudhuari NK, Danenberg P, et al. Fluorinated pyrimidines, a new class of tumor-inhibitory com-pounds. Nature 1957; 179: 663–6.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Backus HH, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mecha-nism. Biochim Biophys Acta 2002; 1587 (2-3): 194–205.
   PubMed Web of Science ®Google Scholar
• Jain RK. Understanding barriers to drug delivery: high resolution in vivo imaging is key. Clin Cancer Res 1999; 7: 1605–6.
   Google Scholar
• Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased microvascular permeability con-tributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res 1993; 53: 3765–70.
   PubMed Web of Science ®Google Scholar
• van der Veen AH, Eggermont AM, Seynhaeve AL, van Tiel, ten Hagen TL. Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sar-coma bearing rats. Int J Cancer 1998; 77: 901–6.
   Google Scholar